Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Choroideremia Pipeline: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight | 4D Molecular Therapeutics, Roche, Biogen and Many Others

10/04/2021 | 04:39am EST

Choroideremia is an X-linked chorioretinal dystrophy characterized by progressive degeneration of the choroid, retinal pigment epithelium and retina. This disease is caused by mutations in the X-linked CHM gene encoding a Ras-related GTPase Rab escort protein (REP)-1, which is extremely important for the retinal function. Choroideremia is characterized by extensive loss of all retinal layers in the eyes.

DelveInsight's, "Choroideremia Pipeline Insight, 2021" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Choroideremia pipeline landscapes. It comprises Choroideremia pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Choroideremia therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Choroideremia pipeline products.

Some of the key takeaways from the Choroideremia Pipeline Report*Major companies such as NightstaRx Ltd/Biogen, 4D Molecular Therapeutics, Curative Biotech, Therapeutics, Spark therapeutics/Roche, and others are developing potential drug candidates to improve the Choroideremia treatment scenario. * In June 2021, NightstaRx Ltd announced that the results from Phase III did not satisfy the primary endpoint and secondary efficacy endpoints. Therefore, they will evaluate the results before confirming the next step of the study. *4D therapeutics is developing and investigating its lead product candidate 4D-110 in an ongoing Phase I dose-escalation clinical trial in patients with choroideremia related to mutations in the CHM gene. *In February 2019, Roche entered into a definitive merger agreement to acquire Spark Therapeutics and its clinical assets, including SPK-7001 for choroideremia in Phase I/II.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight

Some of Choroideremia Companies are:*4D Molecular Therapeutics *Roche *Biogen *Curative Biotechnology *And Many Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight

DelveInsight's Choroideremia report covers around 50+ products under different phases of clinical development like*Late-stage products (Phase II and Phase II/III) *Mid-stage products (Phase II and Phase II/III) *Early-stage products (Phase I/II and Phase I) along with the details of *Pre-clinical and Discovery stage candidates *Discontinued & Inactive candidates *Route of Administration

Choroideremia Therapies:*4D-110 *RG 6367 *BIIB111 *Metformin *And Many Others

Current Choroideremia Treatment Scenario and Choroideremia Emerging Therapies:*How many companies are developing Choroideremia drugs? *How many Choroideremia drugs are developed by each company? *How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Choroideremia? *What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Choroideremia therapeutics? *What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? *What are the clinical studies going on for Choroideremia and their status? *What are the key designations that have been granted to the emerging drugs?

Request for Free Sample Report: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight

Table of Contents:

Introduction

Executive Summary

Choroideremia: Overview

Pipeline Therapeutics

* Comparative Analysis

Therapeutic Assessment

Choroideremia - DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Choroideremia Collaboration Deals

Late Stage Products (Phase III)

* Comparative Analysis

BIIB111: Biogen

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

* Comparative Analysis

4D110: 4D Molecular therapeutics

Drug profiles in the detailed report.....

Preclinical stage products

* Comparative Analysis

Metformin: Curative Biotechnology

Drug profiles in the detailed report.....

Inactive Products

* Comparative Analysis

Choroideremia Key Companies

Choroideremia Key Products

Choroideremia- Unmet Needs

Choroideremia- Market Drivers and Barriers

Choroideremia- Future Perspectives and Conclusion

Choroideremia Analyst Views

Choroideremia Key Companies

Appendix

About Delveinsight:

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

Address:304 S. Jones Blvd #2432

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com/report-store/choroideremia-pipeline-insight

Source: www.abnewswire.com

.

(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
4D MOLECULAR THERAPEUTICS, INC. -0.91% 22.79 Delayed Quote.-44.51%
CONNECTYX TECH -6.18% 0.0698 End-of-day quote.376.82%
ROCHE HOLDING AG 1.71% 365.8 Delayed Quote.16.39%
All news about 4D MOLECULAR THERAPEUTICS, INC.
11/234D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2021 C..
AQ
11/104D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and P..
PU
11/104D MOLECULAR THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condi..
AQ
11/104D Molecular Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine..
CI
11/10Earnings Flash (FDMT) 4D MOLECULAR THERAPEUTICS Reports Q3 Revenue $1.4M
MT
11/104D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and P..
AQ
10/294D Molecular Therapeutics Prices Stock Offering at $25 Per Share; Shares Decline
MT
10/294D Molecular Therapeutics Prices Stock Offering at $25 Per Share
MT
10/284D Molecular Therapeutics Announces Pricing of Public Offering of Common Stock
GL
10/274D Molecular Therapeutics Commences Public Offering of 4.5 Million Common Shares
MT
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 18,3 M - -
Net income 2021 -71,7 M - -
Net cash 2021 318 M - -
P/E ratio 2021 -8,95x
Yield 2021 -
Capitalization 739 M 739 M -
EV / Sales 2021 23,0x
EV / Sales 2022 351x
Nbr of Employees 121
Free-Float 90,4%
Chart 4D MOLECULAR THERAPEUTICS, INC.
Duration : Period :
4D Molecular Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 4D MOLECULAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 23,00 $
Average target price 50,33 $
Spread / Average Target 119%
EPS Revisions
Managers and Directors
David H. Kirn President, Chief Executive Officer & Director
August J. Moretti Chief Financial Officer
John F. Milligan Executive Chairman
Melissa Kotterman Vice President-Discovery & Engineering
Fred Kamal Chief Operating & Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
4D MOLECULAR THERAPEUTICS, INC.-44.51%739
MODERNA, INC.237.35%142 893
LONZA GROUP AG30.63%59 859
IQVIA HOLDINGS INC.44.63%49 504
SEAGEN INC.-8.64%29 257
CELLTRION, INC.-42.34%23 827